GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » YoY EBITDA Growth

Tryptamine Therapeutics (ASX:TYP) YoY EBITDA Growth : 89.53% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Tryptamine Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 89.53%.

Tryptamine Therapeutics's EBITDA per Share for the six months ended in Dec. 2023 was A$-0.01.

Tryptamine Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Tryptamine Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics YoY EBITDA Growth Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
YoY EBITDA Growth
Get a 7-Day Free Trial - -98.89 -10.06 41.12 43.97

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 5.31 89.66 19.63 233.33 89.53

Tryptamine Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Tryptamine Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (A: Jun. 2023 )
=(EBITDA per Share (A: Jun. 2023 )-EBITDA per Share (A: Jun. 2022 ))/ | EBITDA per Share (A: Jun. 2022 ) |
=(-0.065--0.116)/ | -0.116 |
=43.97 %

Tryptamine Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-0.009--0.086)/ | -0.086 |
=89.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tryptamine Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » YoY EBITDA Growth
Comparable Companies
ASX:NC6 ASX:ILA ASX:HXL ASX:ANR ASX:NYR ASX:RGS ASX:NSB ASX:1AD ASX:ZLD ASX:MEM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
Website
https://www.exopharm.com
Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines